Gyrodyne, LLC — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Gyrodyne owns and manages medical-office and industrial properties in Suffolk and Westchester Counties, New York. It is pursuing property entitlements and sales, with the stated aim of distributing proceeds, liquidating and dissolving the company.
Financial position and operating metrics
- Liquidation-basis net assets: $30.72 million at December 31, 2023, versus $30.37 million a year earlier. Estimated liquidation value was $19.51 per share, based on 1,574,308 shares then outstanding. These estimates depend on property-sale values and projected costs and are not a guarantee of distributions.
- Post-year-end share offering: In March 2024, Gyrodyne issued 625,000 shares at $8 per share, raising $5.0 million gross and approximately $4.4 million net. Adjusting the December 2023 estimate for the offering gives net assets of $35.46 million, or $16.12 per share, based on 2,199,308 shares.
- Assets and liquidity: Total assets were $57.40 million, including real estate held for sale valued at $53.78 million and cash of $3.49 million. Total liabilities were $26.68 million, including estimated liquidation and operating costs net of receipts of $11.11 million.
- Debt: Mortgage loans totaled $10.98 million, versus $9.76 million in 2022. This includes two Flowerfield loans at 3.85% fixed interest, a Cortlandt loan at 3.75% fixed through its initial term, and a $1.5 million working-capital loan bearing interest at 1.5% above Wall Street prime. The company reported compliance with its Flowerfield loan covenants at year-end.
- Operating cash generation: 2023 rent and reimbursements were $3.13 million; operating costs were $1.71 million; and net operating income was $1.42 million. The filing presents liquidation-basis statements rather than conventional income and cash-flow statements, so a standard net profit, margin, or full cash-flow comparison is not provided in the supplied text.
- Portfolio: The properties had 158,641 rentable square feet and were 86% leased at year-end, compared with 85% and 37 tenants in 2022; 2023 had 35 tenants. Annual base rent was approximately $2.60 million. Flowerfield was 85% occupied and Cortlandt Manor 92% occupied.
Changes versus 2022
- Net assets increased $353,535. A $110,000 increase in real-estate value and changes to retention incentives and director compensation were partly offset by higher costs, including shareholder-activism response expenses, an estimated one-year liquidation-timeline extension, and rights-offering and loan-closing fees.
- Real estate was valued at $53.78 million, up $110,000 from 2022; the prior year included an $11.14 million increase in real-estate value. Year-end cash fell from $4.08 million to $3.49 million, while mortgage debt rose by approximately $1.22 million.
- 2023 rental and reimbursement receipts increased from $3.08 million in 2022, and reported net operating income rose from $1.26 million to $1.42 million.
Outlook, material developments and risks
- Management targets final approvals, property sales and completion of liquidation by year-end 2025. It estimated approximately $53.78 million of gross real-estate proceeds and $30.72 million of distributable cash at the end of the liquidation period, before the offering’s net proceeds. Estimates include projected operating receipts, debt payments, selling costs, entitlements, bonuses and liquidation expenses.
- Flowerfield received preliminary approval for an eight-lot subdivision in 2022, but a New York Article 78 proceeding challenges the approvals. A February 6, 2024 court order dismissed claims by some petitioners but allowed claims by three individuals and a neighborhood coalition to proceed; merits briefing remained ahead. Litigation or appeal could delay or affect the sale.
- Cortlandt Manor received Medical Oriented Zoning District designation in March 2023, allowing 150,000 square feet of medical use and 4,000 square feet of retail use. The company plans to sell, not develop, the properties. It expected Flowerfield subdivision approval in mid-2024 and Cortlandt approvals potentially by mid-2025, subject to conditions and delays.
- Gyrodyne spent approximately $449,000 on entitlement work in 2023 and estimated another $1.21 million through the expected liquidation period. There is no assurance that added flexibility will raise sale proceeds enough to exceed the costs.
- Material risks include uncertain property valuations, local approval delays and community opposition, the Article 78 case, real-estate illiquidity, tenant concentration and lease expirations, inflation and interest rates, and unexpected claims or liquidation costs. A 2015 settlement requires arm’s-length property sales at or above 2014 appraised values, potentially limiting sale options. Distributions may be reduced or delayed; the company warns that inadequate reserves could expose shareholders to creditor claims for distributions received.
- The rights-offering proceeds are intended to fund entitlement work, litigation, sale-contract efforts, capital improvements and working capital. Separately, a vendor agreement signed in February 2024 provided for a $200,000 payment and converted a remaining $477,829 balance into a loan payable shortly after a property sale, with interest accruing monthly.
Most important facts for investors to verify
- Progress and outcome of the Article 78 proceeding, including any appeal, and the status of final Flowerfield subdivision and Cortlandt site-plan approvals.
- Independent support for the $53.78 million real-estate valuation and the assumptions behind projected sale proceeds, costs and the estimated $16.12 per-share post-offering liquidation value.
- Actual occupancy, tenant renewals and collections, especially given that leases representing about 83% of scheduled annual rent expire in 2024–2026 and key tenants contribute substantial rental income.
- Debt balances, lender terms and security, the prime-rate-linked loan, the vendor loan, and whether sale timing creates refinancing or liquidity pressure.
- Use of rights-offering proceeds, remaining entitlement and litigation spending, and whether the company can meet its year-end 2025 liquidation target without materially reducing distributions.